Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| pericyte | 7 studies | 26% ± 14% | |
| endothelial cell | 5 studies | 26% ± 11% | |
| astrocyte | 5 studies | 26% ± 6% | |
| type I pneumocyte | 5 studies | 22% ± 4% | |
| smooth muscle cell | 4 studies | 24% ± 3% | |
| type II pneumocyte | 4 studies | 19% ± 5% | |
| epithelial cell | 3 studies | 24% ± 5% | |
| fibroblast | 3 studies | 26% ± 11% | |
| renal principal cell | 3 studies | 25% ± 6% |
Insufficient scRNA-seq data for expression of RGL3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| kidney | 100% | 9146.20 | 89 / 89 | 91% | 23.06 | 821 / 901 |
| thymus | 100% | 18146.49 | 653 / 653 | 90% | 80.99 | 542 / 605 |
| pancreas | 100% | 3309.78 | 328 / 328 | 88% | 17.86 | 156 / 178 |
| liver | 100% | 1866.45 | 226 / 226 | 77% | 12.95 | 311 / 406 |
| adrenal gland | 100% | 3423.72 | 258 / 258 | 64% | 11.74 | 148 / 230 |
| breast | 100% | 2007.06 | 458 / 459 | 62% | 10.06 | 688 / 1118 |
| ovary | 61% | 620.41 | 110 / 180 | 95% | 40.36 | 410 / 430 |
| lung | 100% | 2597.45 | 576 / 578 | 56% | 11.60 | 645 / 1155 |
| prostate | 97% | 1643.53 | 238 / 245 | 49% | 5.29 | 248 / 502 |
| bladder | 86% | 1418.00 | 18 / 21 | 59% | 15.13 | 295 / 504 |
| uterus | 97% | 1560.65 | 165 / 170 | 40% | 11.83 | 184 / 459 |
| stomach | 87% | 2772.26 | 313 / 359 | 31% | 3.65 | 89 / 286 |
| intestine | 62% | 537.11 | 596 / 966 | 39% | 5.46 | 207 / 527 |
| spleen | 100% | 2678.61 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 18.37 | 1 / 1 |
| blood vessel | 100% | 2196.97 | 1333 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 100% | 1986.12 | 1199 / 1204 | 0% | 0 | 0 / 0 |
| heart | 97% | 1658.07 | 837 / 861 | 0% | 0 | 0 / 0 |
| brain | 48% | 317.77 | 1266 / 2642 | 48% | 5.06 | 338 / 705 |
| esophagus | 47% | 316.84 | 673 / 1445 | 31% | 4.32 | 57 / 183 |
| skin | 26% | 144.41 | 472 / 1809 | 25% | 2.63 | 120 / 472 |
| muscle | 40% | 244.92 | 318 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 30% | 2.80 | 24 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 7% | 0.79 | 2 / 29 |
| tonsil | 0% | 0 | 0 / 0 | 4% | 0.49 | 2 / 45 |
| peripheral blood | 1% | 3.50 | 6 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0007265 | Biological process | Ras protein signal transduction |
| GO_0005829 | Cellular component | cytosol |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0005085 | Molecular function | guanyl-nucleotide exchange factor activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | RGL3 |
| Protein name | Ral guanine nucleotide dissociation stimulator-like 3 (RalGDS-like 3) Ral guanine nucleotide dissociation stimulator like 3 |
| Synonyms | |
| Description | FUNCTION: Guanine nucleotide exchange factor (GEF) for Ral-A. Potential effector of GTPase HRas and Ras-related protein M-Ras. Negatively regulates Elk-1-dependent gene induction downstream of HRas and MEKK1 (By similarity). . |
| Accessions | ENST00000589032.1 ENST00000567431.5 H3BRW0 Q3MIN7 ENST00000567080.1 K7EMV7 ENST00000380456.8 [Q3MIN7-1] ENST00000563726.5 K7EIS7 ENST00000393423.7 [Q3MIN7-2] H3BN42 H3BQS8 ENST00000562663.5 |
